Talvey is a bispecific T-cell engaging antibody. It works by binding to two targets simultaneously: the B-cell maturation antigen (BCMA) on multiple myeloma cells and the CD3 receptor on T-cells. This dual binding brings the T-cells into close proximity with the myeloma cells, activating the T-cells to recognize and kill the cancer cells.
Talquetamab
Generic Name/API:Talquetamab- tgvs
Packaging:Single-dose vial
Storage:2°C to 8°C (36°F to 46°F)
Dosage:Single-dose vial
Strength:3 mg/1.5 mL (2 mg/mL) in a single-dose vial 40 mg/mL in a single-dose vial
Indication:TALVEY is a bispecific GPRC5D-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.
Talquetamab (Talvey) is a first-in-class bispecific antibody targeting BCMA and CD3. It is approved for adult patients with multiple myeloma that has progressed after at least four prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody. By bridging T-cells to myeloma cells, it elicits a potent anti-myeloma immune response.
DOSAGE:
Talvey Weekly Dosing Schedule
| Dosing schedule | Day | Dose | |
| Step-up dosing schedule | Day 1
Day 4 Day 7 |
Step up Dose 1
Step up Dose 2 First Treatment Dose |
0.01mg/kg
0.06mg/kg 0.4mg/kg |
| Weekly dosing schedule | One week after first treatment dose and weekly thereafter | Subsequent treatment doses | 0.4mg/kg |
Talvey Bi- weekly Dosing Schedule
| Dosing schedule | Day | Dose | |
| Step-up dosing schedule | Day 1
Day 4 Day 7 Day 10 |
Step up Dose 1
Step up Dose 2 Step up Dose 3 First Treatment Dose |
0.01mg/kg
0.06mg/kg 0.4mg/kg 0.8mg/kg |
| Biweekly (every 2 weeks) dosing schedule | Two weeks after first treatment dose and every 2 weeks thereafter | Subsequent treatment doses | 0.8mg/kg |
ADVERSE REACTIONS:
-
- Cytokine release syndrome (CRS),
- neurological toxicities (such as peripheral neuropathy and posterior reversible encephalopathy syndrome – PRES),
- hematologic toxicities (like neutropenia, anemia, and thrombocytopenia), infections, and
- skin reactions
SIDE EFFECTS:
- changes in sense of taste
- fever
- nail problems
- very dry skin that may affect the mucous membranes (such as the mouth and eyes) • muscle and joint pain
- difficulty swallowing
- feeling very tired
- infected nose, sinuses or throat (cold)
- weight loss
- diarrhea
STORAGE :
2°C to 8°C (36°F to 46°F)
- Cytokine Release Syndrome requires careful monitoring, especially after the initial doses, and protocols for its management are essential.
- Neurological toxicities necessitate close observation for symptoms like confusion, seizures, and vision changes. Infections are a concern, and patients should be monitored for signs of infection and receive appropriate prophylaxis.
- Hematologic toxicities require regular blood count monitoring and potential dose adjustments or interruptions.
- Skin reactions, including rash and pruritus, are also common and should be managed proactively.
FAQ
Who is Talvey approved for?
Talvey is currently approved for adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. It is important to note that treatment decisions are always personalized based on individual patient characteristics and disease status.
How is Talvey administered?
Talvey is administered subcutaneously (under the skin) by a healthcare professional. The initial doses are given in a step-up dosing schedule to help manage potential side effects, particularly cytokine release syndrome. This step-up schedule allows the body to gradually adapt to the medication.
What are the most common side effects of Talvey?
The most common side effects associated with Talvey include cytokine release syndrome (CRS), infections (such as upper respiratory tract infections and pneumonia), fatigue, nausea, diarrhea, muscle pain, and rash. Many of these side effects are manageable with supportive care and dose adjustments.
What is Cytokine Release Syndrome (CRS) and how is it managed?
CRS is a serious but potentially manageable side effect that can occur when T-cells are activated by immunotherapy. Symptoms can range from flu-like symptoms (fever, chills, aches) to more severe issues like low blood pressure and difficulty breathing. Patients are closely monitored for CRS, especially during the initial treatment cycles. Management may involve withholding Talvey, administering corticosteroids, or using other supportive therapies like tocilizumab.
Are there any specific monitoring requirements for patients on Talvey?
Yes, patients treated with Talvey require close monitoring. This includes regular blood tests to check for changes in blood counts, kidney and liver function, and inflammatory markers. Patients are also closely observed for signs and symptoms of CRS, infections, and neurological events.
What are the potential risks or serious side effects associated with Talvey?
In addition to CRS, serious side effects can include severe infections, neurological toxicities (such as neurotoxicity with reversible symptoms, or PRES – posterior reversible encephalopathy syndrome), and hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS). It is crucial for patients to report any new or worsening symptoms immediately to their healthcare team.
Can Talvey be used in combination with other myeloma treatments?
While Talvey is approved as a monotherapy for previously treated patients, ongoing clinical trials are investigating its use in combination with other established myeloma therapies to potentially enhance efficacy and overcome resistance mechanisms. The optimal combination strategies are still being defined.
What is the typical treatment schedule and duration for Talvey?
Talvey is typically administered weekly for the first two cycles, then every two weeks for subsequent cycles. The duration of treatment is determined by the patient’s response to therapy, tolerability, and the discretion of the treating physician. Treatment may continue until disease progression or unacceptable toxicity.
What is the price of Talvey (Talquetamab) injection in India?
The price of Talvey (Talquetamab) injection in India varies as it is not yet locally marketed and must be procured on request. Supplier availability, import duties, and currency fluctuations influence final pricing. For up-to-date cost, contact 24/7QualityMeds at +91 9967979080.
How to buy Talvey (Talquetamab) injection online in India?
To buy Talvey (Talquetamab) injection in India at a genuine price, contact 24/7QualityMeds. We assist with prescription verification, import compliance, sourcing from trusted suppliers, and ensure safe delivery to your location.
